According to the WGCNA, DEGI analysis and PPI network, CCL19 was identified as an immune-related biomarker of DN, which was then confirmed in another independent dataset and by western blotting and a high glucose stimulation experiment, suggesting that CCL19 plays a key role in the pathogenesis of DN. Here, CCL19 is linked to liver dysplastic nodule.